Tag: Antibody

‘Ab-CoV’ can be a vital resource for researchers to develop therapeutic strategies against new variants of Coronaviruses by facilitating antibody engineering and immune escape analysis

A broadly neutralizing highly potent human monoclonal antibody developed in India against multiple emerging SARS-CoV-2 variants

The researchers began by analysing over 80 different neutralising antibodies reported to be generated after vaccination against the surface spike protein of SARS-CoV-2, the virus that causes COVID-19

100% of test serum samples showed neutralization of the Delta variant and more than 90% of serum samples showed neutralization of the Omicron variant

Casirivimab and Imdevimab is indicated for restricted use in emergency situation for the treatment of mild to moderate COVID-19 in patients who are at high risk of severe COVID-19.............................

Casirivimab and Imdevimab is indicated for the treatment of mild to moderate Covid-19 in high-risk patients........................

The test targets antibodies against the spike protein and plays an important part in characterizing a vaccine-induced immune response..........................

A new study by the ICGEB-Emory Vaccine Center offers hope to improve plasma therapy regimen in India..................

Syngene developed the IgG based ELISA at its research facility in Bengaluru and partnered with HiMedia to manufacture and commercialize the product. HiMedia is seeking approval from the Central Drugs Standard Control Organisation (CDSCO) and will launch the kits once approval is in place...................

Abbott's SARS-CoV-2 IgG test can be used for large-scale antibody testing, in line with the ICMR recommendation for the use of IgG CLIA (Chemiluminescence immunoassay) tests. It has demonstrated reliable results with 99.6% specificity and 100% sensitivity for patients tested 14 days or more after symptoms started...................